A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers

• Drug: PF-04418948
  
  solution, 30 mg, single
• Drug: PF-04418948
  
  solution, 100 mg, single
• Drug: PF-04418948
  
  solution, 300 mg, single
• Drug: PF-04418948
  
  solution, 1000 mg, single
• Drug: PF-04418948
  
  solution, 3000 mg, single
• Drug: PF-04418948
  
  solution, 4500 mg, single
• Drug: PF-04418948
  
  solution, 6000 mg, single

• Experimental: PF-04418948 30 mg
  
  Intervention: Drug: PF-04418948
• Experimental: PF-04418948 100 mg
  
  Intervention: Drug: PF-04418948
• Experimental: PF-04418948 300 mg
  
  Intervention: Drug: PF-04418948
• Experimental: PF-04418948 1000 mg
  
  Intervention: Drug: PF-04418948
• Experimental: PF-04418948 3000 mg
  
  Intervention: Drug: PF-04418948
• Experimental: PF-04418948 4500 mg
  
  Intervention: Drug: PF-04418948
• Experimental: PF-04418948 6000 mg
  
  Intervention: Drug: PF-04418948

Inclusion Criteria:

• Healthy male subjects between the ages of 18 and 55 years.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m^2; and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• A positive urine drug screen.
• History of regular alcohol consumption exceeding 21 drinks/week for males.